03 Apr. 2012 posted by EuroBioForum
The Board of Governors of the Wellcome Trust has approved the creation of a new business that will invest in emerging businesses and technologies in the healthcare and life sciences sectors.
The business's initial capital will be £200 million, drawn from the Wellcome Trust's endowment. The business is currently operating under the working title Project Sigma, and a name and brand identity will be announced shortly.
Sigma will be a directly owned and managed business that will seek to deliver attractive returns on the capital it invests. It will provide financial resources with which to advance the Wellcome Trust's vision of achieving extraordinary improvements in human and animal health by supporting the brightest minds in biomedical research and the medical humanities.